DeHeng Law Offices (Hangzhou)

Recent Deals

  • 2023/8/1

    DeHeng Lawyers Won a Dispute Case over the Joint and Several Liabilities of a One-Person Company Shareholder After Two Years of Trial

    Recently, DeHeng won the judgment in the Beijing Higher People’s Court in a case where Company A represented by DeHeng sued Company B, a one-person company, and its original shareholder Company C, and current shareholder Company D: the court finally determined that Company B and its shareholders should jointly and severally compensate Company A for investment losses of about RMB 100 million. This case is rare in which a listed company, as a one-person corporate shareholder, is judged to be jointly and severally liable for “audit failure.”

  • 2023/7/28

    DeHeng Advised YIFI Laser on Its IPO the STAR Market of SSE

    On July 28, 2023, Wuhan YIFI Laser Co., Ltd. (“YIFI Laser,” stock code: 688646) was officially listed on the STAR Market of the Shanghai Stock Exchange (SSE), and became the first stock of cylindrical full-tab battery intelligent equipment manufacturing.

  • 2023/4/14

    DeHeng Advised DINGS' on Listing on Beijing Stock Exchange

    On April 13, 2023, Jiangsu DINGS' Intelligent Control Technology Co., Ltd. ("DINGS" for short, stock code: 873593) was successfully listed on the Beijing Stock Exchange, and it became the first Changzhou-based A-share listed company to spin off its subsidiary and list it on the A-share market (referred to as "A to A").

  • 2023/4/11

    DeHeng Advised Yongjin Corp. on Issuing A-Shares to Specific Objects

    Recently, Zhejiang Yongjin Metal Technology Co., Ltd. (stock name: Yongjin Corp., stock code: 603995) completed the issuance of A-shares to specific objects, with 44,411,547 shares issued to specific objects at the price of RMB 27.02 per share, raising a total of RMB 1,199,999,999.94.

  • 2023/4/11

    DeHeng Advised Haisen Pharma on Listing on the Main Board of SZSE

    On April 10, 2023, Zhejiang Haisen Pharmaceutical Co., Ltd. ("Haisen Pharma," stock code: 001367) was successfully listed on the main board of the Shenzhen Stock Exchange, and became one of the first listed enterprises after the introduction of the registration system to the SZSE main board. Haisen Pharma issued 17 million shares at the price of RMB 44.48 per share, and raised RMB 756,160,000, which will be mainly used for technological transformation projects of API production lines with an annual output of 200 tons of atorvastatin calcium, the construction of the R&D center and the multi-functional office building, and for replenishing the working capital.

  • 2023/4/4

    DeHeng Advised Hangzhou Future Sci-Tech City on Issuing the First ABN for Intellectual Property Securitization in Zhejiang Province

    On March 31, 2023, Zhejiang Province's first intellectual property asset-backed note (ABN) scheme, i.e. the Hangzhou Financial Investment Leasing – 2023 Hangzhou Future Sci-Tech City Intellectual Property Installment I Directional Asset-Backed Note, was issued at the National Association of Financial Market Institutional Investors (NAFMII).

total  70  
Search